Not stated in filing (corporate presentation dated November 2026
Filed Nov 12, 2026enGene reports no financial results in this filing; it presents an updated LEGEND pivotal cohort 1 dataset (cut October 29, 2026), a BLA timeline, and cash of $245.8M as of October 31, 2026
The filing carries no revenue, expense, net income, EPS or cash flow figures, so financial performance cannot be assessed. The clinical update shows a complete response rate of 56% at any time (Oct 2026 data cut, up from 54% at the Apr 2026 cut) and a 12-month durable response rate of 43%, but the filing states that data collection and cleaning is ongoing, that the FDA discussion on the label population is ongoing, and that the Phase 2 outcome depends on final results.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash, as of October 31, 2026other | $245.8M | – | – |
| Complete response rate at any time, pivotal cohort 1 (N=120 efficacy evaluable), Oct 2026 data cutother | 56% (CI: 47%, 65%) | – | – |
| Complete response rate at any time, pivotal cohort 1 (n=124), Apr 2026 data cutother | 54% (CI: 45%, 63%) | – | – |
| Duration of response of 12 months or more (Kaplan-Meier estimate), Oct 2026 data cutother | 43% (CI: 30%, 55%) | – | – |
| Duration of response of 12 months or more (Kaplan-Meier estimate), Apr 2026 data cutother | 25% | – | – |
| Median duration of response, Oct 2026 data cutother | 10.1 months (7.5 to NE) | – | – |
| Median duration of response, Apr 2026 data cutother | 8.6 months | – | – |
| Complete response at 12 months (n=110), Oct 2026 data cutother | 24% (CI: 16%, 33%) | – | – |
| Complete response at 12 months (n=98), Apr 2026 data cutother | 13% (CI: 7%, 22%) | – | – |
| Patients with at least one treatment-related adverse event (pivotal cohort 1, N=125), Oct 2026 data cutother | 59% | – | – |
| Patients with Grade 3 treatment-related adverse events (pivotal cohort 1, N=125), Oct 2026 data cutother | 4% | – | – |
| Patients with serious treatment-related adverse events (pivotal cohort 1, N=125), Oct 2026 data cutother | 2% | – | – |
| Dose interruptions due to treatment-related adverse events (pivotal cohort 1), Oct 2026 data cutother | 4% (n=5) | – | – |
| Dose discontinuations due to treatment-related adverse events (pivotal cohort 1), Oct 2026 data cutother | 1% (n=1) | – | – |
| Pivotal cohort 1 enrollment (fully enrolled)other | N = 125 | – | – |
Milestones as stated in the presentation (4Q 2026 to mid-2027) outlook
- NoteBLA initiation: 4Q 2026
- NotePotential BLA approval: 2027
- NoteDetalimogene plus surfactant bladder rinse cohort 6-month data: mid-2027
What drove it
- Company states that the 56% complete response rate at any time is 'within the range observed from approved products' and that durability is 'trending toward range of approved products'. The filing also states that cross-trial comparisons are inherently limited and that no direct comparisons should be made.
- Company states the rate of 12-month durable responses for patients who entered maintenance: '100% of patients who entered maintenance and have been assessed for durability have recorded durable responses' (9 patients pending the DOR assessment).
- Company states that the Phase 2 portion of the LEGEND study may potentially support BLA approval, as indicated by the FDA, and that the outcome depends entirely on final Phase 2 results.
Concerns
- The filing states that data collection and cleaning is ongoing and is subject to change, and that the data reflect the database as of 29 October 2026.
- The Statistical Analysis Plan is described as 'Ongoing discussion with FDA on potential label population'.
- Nine patients are pending the 12-month durability assessment. The filing notes that patients censored at the start of new treatment can produce an overestimate in the Kaplan-Meier model.
- The 12-month complete response rate is 24% (CI: 16%, 33%), with 1 patient pending. The filing presents this as a supportive endpoint not included in approved product labels.
- The filing states that the Phase 2 outcome depends entirely on the final results of Phase 2 clinical testing.
- The filing includes a cautionary statement that the preliminary clinical data may not predict final trial results.
- The comparison table of approved products is not based on head-to-head or comparator studies, per the filing's own disclaimer.
What to watch
- BLA initiation, scheduled for 4Q 2026 per the presentation.
- Outcome of the ongoing FDA discussion on the potential label population and the Statistical Analysis Plan.
- Final pivotal cohort 1 results, including the pending 12-month durability assessments (9 patients) and the 12-month complete response assessment (1 patient pending).
- Surfactant bladder rinse cohort 6-month data, expected mid-2027.
- Potential BLA approval and platform designation decision, expected in 2027.
- FDA confirmation of the 2-8°C storage claim, which the presentation marks as 'Subject to confirmation from the FDA'.
- Expansion of enrolling sites to 35-40 across North America and Europe, from 29 active sites, as stated for the surfactant cohort.
Balance sheet and cash flow
- Cash of $245.8M as of October 31, 2026, per the presentation's footnote 'Cash as of October 31, 2026'.
- Presentation headline: 'Expect to Provide Operating Flexibility through Potential BLA Filing and Approval.'
Analysis
This 8-K (Items 2.02, 7.01 and 8.01) attaches a corporate presentation dated November 2026 and contains no income statement, balance sheet, cash flow statement or guidance on revenue or expenses. The only financial figure is cash of $245.8M as of October 31, 2026, which the company says should provide operating flexibility through the potential BLA filing and approval. No revenue, operating expense, net income, EPS, capital return or debt figures are reported, so the period's financial performance cannot be measured from this document.
The clinical update is the substance of the filing. For the pivotal LEGEND cohort 1 (N=125, BCG-unresponsive high-risk NMIBC with CIS), the complete response rate at any time is 56% (CI: 47%, 65%, n=120) in the October 2026 data cut, against 54% (CI: 45%, 63%, n=124) in the April 2026 cut. The Kaplan-Meier estimate of durable response at 12 months or more is 43% (CI: 30%, 55%), against 25% in the April 2026 cut. The 12-month complete response rate is 24% (CI: 16%, 33%), against 13% (CI: 7%, 22%). The filing states that these figures reflect data as of 29 October 2026 and that data collection and cleaning is ongoing.
Safety figures reported for the same cohort include treatment-related adverse events in 59% of patients, Grade 3 events in 4%, serious events in 2%, dose interruptions in 4% (n=5) and dose discontinuations in 1% (n=1). The filing describes the Grade 1-2 share as 93% of patients with treatment-related events and the median resolution time as 6 days. The company compares these with approved products and with another investigational agent, but the filing itself states that cross-trial comparisons are limited and that no direct comparisons should be drawn.
The filing sets out a timeline of BLA initiation in 4Q 2026, potential approval in 2027 and surfactant-cohort 6-month data in mid-2027. It also records that the FDA discussion on the potential label population is ongoing, and that the Phase 2 outcome depends on final results. The surfactant cohort, which uses a 0.25% polidocanol rinse with a 30-minute detalimogene dwell, is in an early enrollment phase with up to 80 patients planned.
In total, the document offers a clinical update and a timeline, not an earnings report. Readers seeking revenue, margin, EPS or guidance comparisons will not find them here. The verdict reflects the mix of positive directional clinical data and the open items the filing itself lists, not any judgment on financial results.
Not in the filing
stated, not guessed- No income statement: total revenue, cost of sales, gross margin, operating expenses (R&D, G&A), operating loss, interest, tax, net loss and EPS are not reported in this filing.
- No prior-year or prior-quarter financial figures are printed.
- No fiscal period label or period end date for a financial period is stated; the cash figure is a balance as of October 31, 2026.
- No operating or free cash flow figures are reported.
- No debt, total assets or stockholders' equity figures are reported.
- No capital returns (share repurchases, dividends) are reported.
- No previous outlook was provided, so vs_prior_guidance is empty.
- No financial guidance figures (revenue, gross margin, operating expenses, tax rate) are given.
- No quotes from named executives are included in the filing text.
- No share price reaction or analyst consensus is provided and none has been included.
- The 8-K lists Item 2.02 (Results of Operations and Financial Condition), but no financial statements or results table appear in the text provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.